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Fibroid (also called uterine leiomyoma, myoma, leiofibromyoma, 
fibroleiomyoma and fibroma) is a benign tumour that originates from 
the smooth muscles of myometrium and the accompanying connective 
tissue of the uterus. Fibroids are the most common benign tumour in 
females and typically found during the middle and later reproductive 
years seen in 40-50% of women older than 35 years1. It is estimated to 
occur in 40% of menstruating women older than 50 years. Symptoms 
caused by uterine fibroids are frequent indication for hysterectomy. 
Fibroids are often multiple. Most patients with uterine fibroids are 
asymptomatic2. 
 Most common presenting symptoms of fibroids are: 
• Abnormal uterine bleeding. 
• Dysmenorrhoea. 
• Pelvic pain, possibly resulting from intramural degeneration, 
torsion of pedunculated fibroid or uterine contractions. 
• Pelvic pressure. 
• Abdominal distension in case of large fibroid 
• Genitourinary dysfunction, which may manifest as the following: 
o Increased urinary frequency resulting from bladder 
compression. 
o Acute urinary retention. 
o Flank pain resulting from urethral compression 
and hydronephrosis. 
• Infertility. 
• Rarely, lower extremity edema, constipation, or intestinal 
obstruction. 
According to the location fibroids are called Intramural 
fibroids, Subserosal fibroid (sometimes pedunculated), Sub mucosal 
fibroids and cervical fibroids. Intra mural fibroids are the most common 
type causing menorrhagia and dysmenorrhoea. These intra mural 
fibroids can be treated with uterine fibroid embolisation. 
 Various Medical and surgical therapies are used to treat fibroids. 
Medical therapy includes hypo estrogenic drugs, which causes 
temporary reduction in size and relief of symptoms. Surgical treatment 
includes myomectomy or hysterectomy. Uterine fibroid is one of the 
leading causes for hysterectomy today in India and worldwide.  
Transcatheter embolisation of the uterine arteries for symptomatic 
fibroids has become an increasingly important alternative treatment. It is 
highly effective and well tolerated by most patients. Most notably, 
uterine artery embolisation is minimally invasive associated with a short 
recovery period and is uterine sparing.  
 
Estimated 13,000-14,000 UFE procedures are performed annually 
in U.S. (as of 2004). In India uterine fibroid embolization is less popular 
and done in very few centres. This study is to determine the benefits and 
effectiveness of uterine artery embolization in symptomatic uterine 
















































The aim of this study is to analyse the effectiveness, technique, 
complication and outcome after uterine artery embolisation in patients 






























TREATMENT OPTIONS FOR FIBROID 
The ideal treatment should be minimally invasive, cost-effective, 
efficacious and tolerable with minimal side effects and have a low 
incidence of fibroid recurrence. Treatment for symptomatic uterine 
fibroid can be conservative or definitive  
Conservative approaches are preferred for those who want to 
conserve the uterus for further child bearing or menstrual function. Both 
medical and surgical approaches are available for conservative 
management 
MEDICAL METHODS: 
Various hypo-estrogenic agents are tried to reduce the size of 
fibroid and to reduce the symptoms. They have various side effects and 
their effects are short lasting. E.g.: Ocps, Progestin, GnRH analogue, 
etc. 
• Oral contraceptive pills3 often are used to control menorrhagia 
and dysmenorrhoea. A drawback of this treatment is that the 
fibroids may increase slightly in size. For some women, the 
benefits of hormonal contraception outweigh the risk of side 
effects like weight gain, thromboembolism, etc. Hence OCP’s 
rarely used in patients with fibroids.  
• Gonadotropin–releasing hormone (GnRH) 4 agonists. These 
drugs reduce menorrhagia and can shrink fibroids. They 
sometimes are used pre-operatively to reduce the risk of bleeding. 
GnRH agonists have many side effects, including osteoporosis, 
vaginal dryness, and night sweats. For these reasons, they are 
used only for short periods (less than 6 months). Fibroids usually 
return to their previous size on stopping the treatment. 
• Progestin– Levonorgestrel releasing intrauterine device5 is an 
option for women with fibroids that do not distort the endometrial 
cavity. It reduces menorrhagia and dysmenorrhoea but does not 
treat the fibroids. LNG intrauterine devices can be used for 
5years. 
•  RU-486 (mifepristone) 5-10 mg per day6 used upto 6 months has 
also been shown to reduce fibroid size by half. This drug can also 
be used to reduce pelvic pain, bladder pressure and low back pain. 
Low doses of Mifepristone may reduce the size of fibroids in 
preparation for surgery to remove them. It may also help some 
patients avoid surgery entirely by shrinking the fibroids and the 
problems they are causing. Side effects related to low oestrogen, 
seen with GnRH analogs, may be less common. RU-486 can 
induce miscarriage, it should be used with caution if a woman is 
trying to conceive. 
• Danazol4 has been used to reduce Menorrhagia in women with 
fibroids, but it does not shrink the size of fibroids. Danazol is 
androgenic that can cause serious side effects including weight 
gain, muscle cramps, decreased breast size, hirsutism, mood 
changes,  depression, acne, decreased high density lipoprotein  
levels and increased liver enzyme levels. 
• The selective progesterone receptor modulator asoprisnil7 (10 and 
25 mg daily for 3 months) are given to women with symptomatic 
fibroids who are scheduled for hysterectomy. Asoprisnil reduces 
uterine blood flow (determined by resistance index and pulsatility 
index) and volume of the largest fibroid and the uterus. Analysis 
of menstrual pictogram scores showed a significant decrease in 
frequency and intensity of bleeding compared with placebo. 
Further studies are required to evaluate safety and efficacy of 
asoprisnil when administered for long period.  
CONSERVATIVE SURGICAL TREATMENT: 
• Myomectomy: 
Myomectomy8 (abdominal/ laparoscopic) traditionally has been 
done to improve infertility in women who has uterine fibroids. Over the 
past ten years it has been utilized more routinely as a treatment for any 
women with fibroids who wish to conceive. Myomectomy may be done 




Hysteroscopy9 can be used to remove submucous fibroids that 
protrude into the endometrial cavity. A resectoscope is inserted through 
the hysteroscope. The resectoscope destroys fibroids with electrocautery 
or a laser beam. Although it cannot remove intramural and subserous 
fibroids, it often can control the bleeding. In most cases, an overnight 
stay in the hospital is only necessary. 
• Endometrial Ablation: 
Endometrial ablation can be accomplished by either using a 
hysteroscope dissect and cauterize the endometrium or by applying heat 
to the Endometrium. This cannot be used in patient who wants further 
pregnancy.  
• Myolysis10: 
There are two surgical methods which share the common concept of 
destroying the fibroids in uterus without necessarily removing them. 
 
o Myomacoagulation10: 
       This approach is best used either alone or in combination with 
laparoscopic myomectomy when multiple tumours are encountered. In 
this technique myoma tissue is destroyed by Nd: YAG laser or bipolar 
cautery. It helps avoid tedious laparoscopic removal of multiple 
fibroids.Combination of myolysis and endometrial ablation may reduce 
the need for subsequent procedures in patients with persistent bleeding. 
o Cryomyolysis: 
     This procedure uses a probe which freezes the tumour, causing death 
and shrinkage of the tumour. Cryomyolysis has not been broadly used, 
mostly because the instrumentation is very expensive 
• Magnetic Resonance Imaging–Guided Ultrasound Surgery11. 
In this new approach, ultrasound waves are used to destroy fibroids. 
The waves are directed at the fibroids through the skin with the help of 
magnetic resonance imaging. Studies show that women have improved 
symptoms up to 1 year after having the procedure.  Long-term efficacy 
is currently under study. 
RADICAL TREATMENT: 
• Hysterectomy: 
 Hysterectomy either abdominal or laparoscopic is the most radical 
surgical procedure for the treatment of uterine fibroids. It involves the 
removal of the uterus from pelvis, with preservation of the ovaries. 
Some of the complications that are associated with hysterectomy are the 
loss of support of the pelvic floor, risk involving regional or general 
anaesthesia, blood loss which may need blood transfusions. Damage to 
the Bladder, Bowels and ureter are possible and involves additional 
morbidity and mortality. It needs long post operative stay at hospital. 
• Uterine Artery Embolisation: 
 UAE for the fibroid uterus was first used in 199512. Since then it has 
be evolving as the primary treatment for fibroid. It is safe, simple, short 
hospital stay with less complication with high efficacy. Ischemia of 
uterine fibroids may also be achieved by a variety of techniques. 
Laparoscopic uterine artery occlusion13 has been shown to yield 
equivalent results to UFE in the short term utilizing bipolar coagulation 
or clips. Another procedure of temporary bilateral uterine occlusion 
performed with intravaginal, 14 “incision less” application of paracervical 
clamp with integrated audible Doppler ultrasound to treat uterine 




































REVIEW OF LITERATURE 
Embolization15 is defined as the "therapeutic introduction of various 
substances into the circulation to occlude selective vessels, either to arrest or 
prevent haemorrhage, to devitalize a structure, tumour or organ." 
Drs.Lussenhop and Spence15 first occluded a cerebral arteriovenous 
malformation under radiographic and catheter guidance in 1960. Charles 
Dotter is acknowledged as founder of the specialty from his landmark work 
on angioplasty, first published in circulation in 1960. Another who 
contributed early was           Dr. Baum, who developed techniques for 
controlling G-I bleeding using Vasopressin. 
        Following Drs.Lussenhops and Doppman in the USA, Japanese physicians 
developed selective catheter techniques for treating spinal cord AVMs. In 1972,    
Dr. Dotter and Dr. Rosch15 again developed techniques for controlling 
bleeding due to ulcer disease by embolizing autologous clots. Dr. White et. 
al15. first used this technique successfully in 1974 to actually control ulcer 
bleeding with the survival of patient survived. Early in the 1970s, many 
radiologists began to use embolotherapy for lifesaving haemorrhages. 
Since 1960's, embolization of uterine artery has been used to treat post 
partum haemorrhage. Uterine artery embolisation was used to control heavy 
bleeding from cervical carcinoma. A recent case report from Ottawa hospital, 
Canada16 says that uterine artery embolisation was used to control bleeding 
from cervical pregnancy. The embolic agents used are polyvinyl 
alcohol , acryilic spheres, gelfoam ,steel coils and these are approved by the 
U.S. Food and Drug Administration (FDA) for this purpose. 
Uterine Artery Embolization for fibroid uterus was first used as a 
technique to limit blood loss during surgical removal of fibroids, and 
performed well before the surgery. However, it was found that after 
embolization and while awaiting surgery many patients no longer had 
symptoms and frequently the operation itself proved to be unnecessary. UAE 
was introduced as a treatment for fibroids in 1992 in Paris by Dr. Jacques-
Henri Ravina12, a gynaecologist. The treatment was first performed in the 
U.S. at the University of California at Los Angeles (UCLA). There are now 
many such centres on the world performing UAE to treat uterine fibroids. 
Mahmood et al 17 (2002) from Department of Vascular and 
Interventional Radiology, Stanford University analyzed the outcomes of 111 
consecutive patients who underwent abdominal myomectomy (n = 44) or 
fibroid embolization (n = 67) over a 30-month period. The 
respective observed success rates in abdominal myomectomy and uterine 
fibroid embolization patients were 64% versus 92% for menorrhagia (p < 
0.05), 54% versus 74% for pain (not significant), and 91% versus 76% for 
mass effect (p < 0.05). The complication rates were 25% (abdominal 
myomectomy) and 11% (uterine fibroid embolization)(p < 0.05). The 
respective secondary end points for the two procedures were 2.9 versus 0 
days mean hospital stay, 8.7 versus 5.1 days of narcotics use, and 36 versus 8 
days until resumption of normal activities. These differences were all 
statistically significant. He concluded that uterine fibroid embolization was a 
less invasive and safer treatment option in women with symptomatic 
leiomyomas than myomectomy. Menorrhagia may be better controlled with 
embolization and myomectomy may be a better option in patients with 
mass effect. Both procedures were equally effective in controlling pain. 
Spies18 (1999) from Georgetown University Medical Centre presented 
results of 61 patients who underwent uterine fibroid embolization. During a 16-
month period menstrual bleeding was improved in 89%, with 81% of patients 
moderately to marked improvement. Pelvic pain and pressure was improved in 
96% of patients, with moderate to marked improvement in 79%. At initial 
imaging follow-up (mean, 4.4 months post procedure), median uterine volume 
decreased 34% (P = .0001) and the median dominant fibroid volume decreased 
50% (P = .0001). Imaging at 1 year (mean, 12.3 months) after the procedure 
showed continued reduction with a median uterine volume reduction of 48% (P 
= .0002) and median dominant fibroid volume decrease of 78% (P = .0002). The 
authors concluded that UFE appears effective in controlling symptoms and 
substantially reducing fibroid volume with few complications. 
Pron et al 19 (2003) reported on the Ontario Uterine Fibroid Embolization 
Trial, which enrolled 555 women. The median follow-up was 8.9 months. 
Menorrhagia improved in 83% of women following the procedure, 
dysmenorrhea improved in 77% and urinary frequency improved in 86% of 
women. The mean fibroid volume reduction for the dominant fibroid was 33% 
at 3 months. Amenorrhea occurred in 8% of women. The complication-related 
hysterectomy rate in the Ontario UFE Trial was 1.5% within 3 months of the 
embolization.12 of the 8 procedures, 2 were for infection, 4 for persistent post 
embolization pain, 1 for a 10 cm prolapsed leiomyoma, and 1 for persistent 
vaginal bleeding. 
Spies J, et al 20 (2004) done a multicenter control trail comparing the 
Outcome of Uterine Embolization and Hysterectomy for Leiomyomas. Study 
published in American Journal of Obstetrics & Gynaecology. Spies J, et al 
states that shorter hospital stay with UFE: < one day versus Hysterectomy 2.3 
days. Return to work UFE: 10.7 days versus Hysterectomy: 32.5 days and 
Fewer complications (after 30 days) UFE: 12.7% versus Hysterectomy: 32% 
Jain et al 21 (2004) from All India Institute of Medical Sciences, New 
Delhi carried out a study determines the effectiveness of uterine artery 
embolization (UAE) as a primary treatment of symptomatic fibroids. Study was 
carried out in total of 32 patients aged 25–49 years (mean 40.9 years). 
Procedure was carried out through unilateral femoral puncture using poly vinyl 
alcohol (PVA) particles 355–500 µm in size. All 32 patients had successful 
procedures. Overall, 25 patients responded, giving a clinical success rate of 
78.12%. Mean reduction in volume of fibroid was 59.7% (range 31.6–83.3%) 
and 75.5 %( range 46.2–96.8%) on USG at 3 and 12 months. He concluded that 
uterine artery embolization leads to good technical success and fibroid volume 
reduction. 
Tranquart et al 22 (2005) from France evaluated the sonographic feature 
of 58 women following uterine artery embolization and to assess the efficacy of 
embolization as the primary treatment of fibroids. Most patients were improved 
or free of symptoms at 3 months (90%), 6 months (92%) and 1 year (87%) and 
all monitored patients were free of symptoms at 2 years. Clinical failure of 
treatment occurred in only two cases (3%). Progressive significant reduction in 
fibroid size with reference to the baseline was demonstrated during follow-up 
from 3 months (29%) to 24 months (86%). He concluded that uterine artery 
embolization was a valuable endovascular method for the treatment of fibroids, 
resulting in marked reduction in fibroid size and disappearance of intrafibroid 
vessels without reduction in uterine vascularisation  
Albert. J. Smeets et al 23 (2009) from Department of Radiology of St. 
Elisabeth Ziekenhuis in Netherlands evaluated the controversial issues of 
Uterine artery embolization (UAE) in patients with a large fibroid burden 
.Seventy-one consecutive patients (mean age, 42.5 years; median, 40 years; 
range, 25–52 years) with a large fibroid burden were treated by UAE between 
August 2000 and April 2005. There were no serious complications of UAE. 
During a mean follow-up of 48 months (median, 59 months; range, 6–
106 months), 10 of 71 patients (14%) had a hysterectomy. Mean volume 
reduction of the fibroid and uterus was 44 and 43%. Mean infarction rate of the 
fibroid and overall fibroid infarction rate was 86 and 87%. In the vast majority 
of patients there was a substantial improvement of symptoms. Clinical results 
were similar in patients with a dominant fibroid >10 cm and in patients with 
large uterine volumes by diffuse fibroid disease. Their results indicate that the 
risk of serious complications after UAE in patients with a large fibroid burden 
was not increased. Moreover clinical long-term results are as good as in other 
patients who are treated with UAE. Therefore a large fibroid burden should not 
be considered a contraindication for UAE. 
In another article on Uterine Fibroid Embolization Goodwin24 and Spies 
highlight few contraindications to the procedure like pregnancy, suspected 
cancer, active infection indeterminate endometrial or adnexal abnormalities. 
They also cite the U.K. Hysterectomy or Percutaneous Embolisation for Uterine 
Leiomyomata (HOPEFUL)25 study, which showed 2.6% incidence of 
septicaemia after uterine fibroid embolization, with 1.1% of the women 
requiring emergency hysterectomy. Severe infection, often necessitating urgent 
hysterectomy, was a rare but well-established complication of uterine fibroid 
embolization. 
The Fibroid registry26 (Fibroid Registry for Outcomes Data) of 3160 
patients showed an emergency hysterectomy rate of only 0.09% at 30 days. 
Emergency hysterectomy for bleeding has been described 4 months after uterine 
fibroid embolization. 
In the Randomized Clinical Embolization versus Hysterectomy 
(EMMY) 27 trial, researchers in The Netherlands found those six weeks 
after treatment, women who underwent UFE reported higher satisfaction 
scores than those who had hysterectomies. Two years later, 90 percent of 
the women in both categories said they were satisfied with their therapies, 
the researchers reported in the March 2008 edition of Radiology. 
Ninety percent of women who underwent UFE avoided a 
hysterectomy, said Scott Goodwin, M.D., 28 the lead author and a 
professor and chair of the Department of Radiological Sciences in the 
School of Medicine at the University of California, Irvine. Study results 
were published in the January 2008 issue of Obstetrics & Gynaecology. 
Research at Georgetown University 29 till 1999, 20.000 to 25,000 
patients has had this procedure world-wide. Their initial results, along 
with those that have been published or presented at scientific meetings, 
says that symptomatic improvement in 85-90% of patients with the large 
majority of patients markedly improved. The improvement rate was 
similar for heavy menstrual bleeding and for pressure and pain symptoms. 
Most patients have rated this procedure as very tolerable and in almost all 
cases hospitalization is necessary for only one night. In some centres, the 
patients are treated and discharged the same day. The expected average 
reduction in the volume of the fibroids is 40-50% in three months, with 
reduction in the overall uterine volume of about 30-40%. Over time, the 
fibroids continue to shrink. With several years follow-up now available, it 
appear that fibroids are successfully treated does not re grow. 
Giovanna Tropeano et al30 from Department of Obstetrics and 
Gynaecology, University Catholic del Sacro Cuore, Italy 
reports  50–60% reduction in fibroid size and 85–95% relief of symptoms  
following UAE. UAE offered shorter hospital stays (1–2 days for UAE 
versus 5–5.8 days for hysterectomy) and recovery times (9.5–28 days for 
UAE versus 36.2–63 days for surgery) and major complication rates (2–
15% for UAE versus 2.7–20% for surgery, in 3 Randomised control trials. 
 Four studies analysing cost-effectiveness found UAE more cost-effective 
than surgery. There is insufficient evidence regarding fertility and 
pregnancy outcome after UAE. They concluded that good quality 
evidence supports the safety and effectiveness of UAE for women with 
symptomatic fibroids. The current available data are insufficient to 
routinely offer UAE to women who wish to preserve or enhance their 
fertility. 
Hayden Homer 31  Department of Obstetrics and Gynaecology, Institute 
for Women’s Health, University College London has said that data on 
pregnancy following uterine artery embolisation (UAE) are scarce, with just 
over 200 pregnancies reported. Two small prospective trials of UAE versus 
surgical intervention suggest increased levels of adverse pregnancy outcomes 
following fibroid embolisation. This study suggests that in the absence of 
more robust evidence, caution should be exercised in recommending UAE to 
women who wants to retain their reproductive ambitions.  
 
Joao and Marisa 32 (2010) studied on pregnancy out come after uterine 
fibroid embolisation. This study shows comparable fertility rates between the 
two primary uterus-sparing treatments uterine fibroid embolization (UFE) 
and surgical myomectomy, which is considered the gold standard for 
symptomatic fibroids in women who wish to conceive. Of the 743 patients 
who received UFE treatment, 74 wanted to conceive and had been unable. 
Most women opted for UFE as a fertility treatment after failure of 
myomectomy or in vitro fertilization or because hysterectomy was the only 
suggested option. Of the 74 women who wanted to become pregnant, 44 of 
them became pregnant (59.5%). There are five (11.3%) ongoing pregnancies 
and 39 (88.7%) finished pregnancies, with 33 successful live births (84.6%), 
four spontaneous abortions (10.3%), one induced abortion and one stillbirth. 
There were 22 caesarean deliveries (66.6%), two preterm deliveries at 36 
weeks (6.1%) and five low birth weights. This study concluded that in the 
future, UFE will probably be a first-line treatment option even for women 
who wish to conceive and are unable due to the presence of uterine fibroids. 
Rashid. S. et al 33 studied the effects of Uterine Artery Embolisation and 
Surgical Treatment on Ovarian Function in Women with Uterine Fibroids. 
Some studies have shown that patients treated with UAE develop amenorrhea 
(with rates varying from 1%–8% and as high as 14%) and have increased 
follicle-stimulating hormone (FSH) levels (within the menopausal range) 
suggesting ovarian dysfunction may occur as a consequence of UAE. This study 
compares the effects of UAE and surgery on ovarian function and menstrual 
cycle characteristics in women with uterine fibroids. The impact of age on 
ovarian function was also studied. All surgical patients had ovarian 
conservation at the time of surgery. Ovarian function assessed by the levels of 
serum FSH were measured on day 3 of the menstrual cycle before treatment, 
and at 6 and 12 months post-treatment and menstrual cycle characteristics. No 
significant difference was found between the two treatment groups in the rate of 
ovarian failure at 12 months (UAE: 11% versus surgery: 18%; P = 0.44. These 
findings provide no evidence that UAE accelerates deterioration in ovarian 
function at 1 year, in comparison with surgery.        
Van der Kooij SM et al 34 (2010) from Department of Radiology, 
Academic Medical Center, Amsterdam compared the clinical outcome and 
health related quality of life (HRQOL), 5 years after uterine artery embolization 
(UAE) or hysterectomy in the treatment of menorrhagia caused by uterine 
fibroids. Patients with symptomatic uterine fibroids who were eligible for 
hysterectomy were assigned randomly 1:1 to hysterectomy or UAE. Endpoints 
after 5 years were re-intervention rates, menorrhagia and HRQOL measures that 
were assessed by validated questionnaires. UAE had a positive effect both on 







































MATERIALS AND METHOD 
In this study 32 patients with fibroid uterus having at least one of the 
following symptoms are selected 
1. Menorrhagia 
2. Dysmenorrhoea 
3. Pressure symptoms like    
• Lower abdominal heaviness 
• Increased frequency of micturation 
•  Constipation 
 
Patients were explained about the uterine fibroid embolisation, an 
alternate method to treat fibroid without hysterectomy. Patients were explained 
about the expected outcomes, side effects and risks involved like perforation of 
arteries, need for emergency laprotomy, possibility of treatment failure and need 
for future hysterectomy. They were also informed about alternative treatment 
options available. Written consent obtained from all patients who were ready to 
participate in the study. Those who accepted to undergo uterine fibroid 
embolisation were subjected to further investigations. 
 
 
Patient Selection Criteria 
• Inclusion criteria 
1. Women with symptomatic fibroid (menstrual disturbances or 
pressure symptoms due to size or pain) who want to retain their uterus 
and avoid surgery.  
2. Solitary or multiple intramural fibroids of less than 7 cm.  
3. Parous women who completed family and age less than 40 yrs.  
4. Women who give consent to undergo uterine artery embolisation 
and participate in study.  
• Exclusion criteria 
1. Women with asymptomatic fibroid.  
2. Infertile women or parous women who want to conserve uterus for 
future pregnancy. 
3. Fibroids of more than 7 cm or with degenerative changes or 
hypovascularity on Doppler study.  
4. Sub mucous or pedunculated Subserosal fibroid.  
5. Previous history of anaphylaxis to contrast. 
6. Systematic illness like HIV, HbsAg +ve, abnormal renal profile, 
Coagulation disorders. 
Study Design: Prospective interventional trial 
Study Place: Institute of Obstetrics and Gynaecology, Chennai. 
Collaborating Unit: Bernard Institute of Radiology, MMC 
Study Population: Women with symptomatic fibroid 
Sample Size: 30 Women with symptomatic fibroid. 
METHODOLOGY: 
        A detailed history was taken to know the severity of symptoms. 
Menorrhagia was assessed by  
Pictorial Blood Loss Assessment Chart (Hallberg et al.)41. Patients were 
asked to keep a detailed menstrual calendar denoting the number of pads used, 
soakage of each pad, duration of flow and passage of clots.  
 
Pictoral blood loss scoring is given below 
 Towels 
1 point – For each lightly stained towel 
5 points - For each moderately soiled towel 
20 points - If the towel is completely saturated with blood 
 Tampons 
1 point - For each lightly stained tampon 
5 points - For each moderately soiled tampon 
20 points - If the tampon is completely saturated with blood 
 Clots 
1 point - For small clot 
5 point - For large clot 
5 point - For flooding 
Pictorial Blood Loss Assessment Chart scoring was done before the 
treatment, 3 months and 6 months after treatment. 
Dysmenorrhoea was assessed by 
 Visual analogue scale42 using a 10-cm line represented the 
continuum.One extremity of the line represents ‘Unbearable pain’ and the other 
extremity represents ‘No pain at all’. The participants were asked to rate the 
degree of pain by making a mark on the line. 
The scores received from the scale is classified into 
1–3 points   mild dysmenorrhea  
4–7 points   moderate dysmenorrhea  
8–10 points severe dysmenorrhea  
  
• Pressure symptoms were assessed by the presence or the absence 




• Basic blood investigations done including Hb%, Blood urea, Serum 
creatinine, HIV, HbsAg, coagulation profile. 
• Usg abdomen and pelvis done to know the location, size, number and 
volume of fibroid. Those who had degenerations (calcification or 
cystic degeneration) are excluded from the study. 
• Doppler Usg done to know the vascularity of fibroid. Hypo vascular 
fibroids are excluded from study.  
• Fractional curettage performed to rule out any associated malignant 
changes in endometrium. 
Patients fit for UFE according to the inclusion criteria were taken up for 
UAE after adequate counselling. Eligible patients were advised to use 
contraception before the procedure and LMP confirmed. 
 




• Inj Dexamethasone 8mg I.V Stat 
• Inj. Pheniramine Maleate I amp I.M Stat  
• Inj. Atropine Iamp I.V.Stat 
Anti biotic prophylaxis: 
• Inj Ampicillin 1gm I.V (ATD) 
Anesthesia/ Sedation: 
• Inj Tramadol 1 amp IM 
Patient position:  Supine 
Approach:  Percutaneous transfemoral approach 
 With aseptic precautions under local anaesthesia femoral puncture was 
made. 
 Internal iliac catheterized with single multipurpose 4F- 5F cobra catheter. 
 Contra-lateral uterine artery was selectively catheterized 
 Angiography and Embolisation was performed using an 800mA 
conventional angiographic unit (SIEMENS). 
 Free flow embolisation was performed just beyond the junction of the 
horizontal and descending portions of the uterine arteries using 
absorbable gelatine sponge shavings or poly vinyl alcohol as the embolic 
agent. 
 Catheter withdrawn up to ipsi-lateral common iliac artery then passed 
into ipsi-lateral internal iliac and ipsi-lateral uterine artery. Embolisation 
done on the ipsi-lateral side. 
 Stagnation of contrast medium was evidenced in the uterine capillary 
network at the end of embolisation, and an absence of flow was depicted 
in the uterine artery by injecting contrast medium into hypogastric 
arteries. 
Endpoint of Embolisation  
Occlusion of the identifiable vessels supplying the fibroids with 
preservation of  normal uterine flow. 
• Evidence of “standing column of contrast” in the uterine artery and 
reflux towards the uterine origin or into the internal iliac artery. 
• Cessations of flow in the ascending uterine artery with residual flow in 
the lower uterine segments supplying the normal myometrium  
Adverse Complications: 
Nil/ Spasm/ Vessel dissection/ Vessel perforation/ Inadvertent 
embolisation/ Reflux of Embolic material into main artery/ Allergic reaction 
 
Post procedure events: 
Patients were observed in high dependence ward for 6 hrs then at least 48 
hrs in the routine wards. All the patients were carefully observed for any 
complications like groin haematoma /retroperitoneal haematoma. Vitals were 
checked. Patients were kept nil per oral for 4 hours. They were advised bed rest 
for 6 hours and then ambulated. Patients were discharged after 48-72 hrs.  
On discharge: 
Patients were advised to report immediately if   
• Any  unbearable  lower abdominal pain  
• Fever or Purulent vaginal discharge 
• Swelling in lower limbs 
• Breathing difficulty 
All of them were advised to maintain menstrual calendar in detail regarding the 
duration, number of pads soiled, clots passed and associated pain. 
Follow up: 
        At the end of 3rd month patients were called and enquired about their 
menstruation, dysmenorrhoea and pressure symptom. USG Pelvis performed to 
know the size & volume of fibroid. Similarly at 6th month patients were called, 
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Menorrhagia was present in all of the subjects. Menorrhagia was assessed 
by Pictoral Blood Loss Assessment Chart. As per Higham et al43 who analysed 
pictoral blood loss, PBAC scoring of >100 is diagnostic of menorrhagia, that is 
blood loss of >80ml with specificity and sensitivity of >80. All patient had 
Pictoral blood loss assessment scoring of >100. Average blood loss scoring in 
this study was 202.66 and ranges from 100-315.Pictoral blood loss assessment 
scoring distribution of the patients before treatment is given below. 





100-150 7 23.33 
151-200 7 23.33 
201-250 11 36.66 
>250 05 16.66 
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 DURATION OF PROCEDURE: 
 In this study we have used unilateral catheterisation. Average total duration 
of the procedure [fluoroscopic exposure time] is 1hour 5minitue. Total duration 
varied from 45minute to 75 minute. 
Table: 10. Duration of procedure 
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FOLLOW UP ANALYSIS: 
 At the end of 3rd month all the 30 patients came for follow up. 
Their menstrual calendar was analysed, symptoms enquired and clinical 
examination was done. USG was done for all patients to assess the size and 
volume of the fibroid. Only 12 patients completed 6th month follow up. Others 
yet to come for follow up at 6 months.  
MENORRHAGIA ON FOLLOW UP 
        At 3 months menstrual blood loss was significantly reduced. 83% had 
moderate to significant improvement in their mean blood loss. Pictoral blood 
loss scoring reduction ranges from 10 to 95% at the 3rd month and 45 to 76% at 
the 6th month. By paired‘t’ test reduction in blood loss at 3 months was highly 
significant with p<0.00001 . 
Table: 13. Distribution of Improvement In Blood Loss After 3 Months 
Improvement In The Blood Loss No. of Subjects % 
Worsening  < 0 0 0 
Remaining The Same 0-10% 0 0 
Mild-10-30% 05 16.67 
Moderate-30-50% 16 53.33 
Good >=50% 09 30.00 
Total Subjects 30 100.00 
 
                                                                                                                                                     
   
 
  
 At 6 months menorrhagia markedly reduced. All the patient had PBLA 










After 3 months 
Before treatment
Before treatment 
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  Uterine fibroid embolisation acts mainly by occluding the blood 
supply to the tumour thus it arrests the growth and causes ischemia and necrosis 
of the tumour. This causes shrinkage of the tumour and prevents grow of new 
fibroids as per long term follow up studies.  
 In this study, mean reduction in the volume at the 3rd month was 
29.91% and at the 6th month was 46.66%. Range of volume reduction varied 
from 9 to 50% at 3 months and 27-65% at 6 months. Paired “t” test was used to 
analyse the volume change after 3 months. It was highly significant with p value  
of <0.0001 at 3 months. 
Table:15. Volume Reduction of Fibroid After 3 Months 
 
No. Of Subjects % 
Worsening 0 0 
Remaining The Same 0-10 01 03.33 
Mild-10-30 17 56.67 
Moderate-30-50 12 40.00 





 In this study moderate to marked reduction in dominant fibroid volume 











































VOLUME REDUCTION GELFOAM Vs PVA: 
 For embolisation we have used gel foam for 15 patients and poly 
vinyl alcohol for 15 patients. On analysing the volume reduction at 3 months, 
mean volume reduction for gel foam and poly vinyl alcohol was 27.86% and 








Worsening 0 0 
Remaining The Same 0-10 0 0 
Mild-10-30 1 08.33 
Moderate-30-50 6 50.00 
Good >=50 5 41.67 
Total Subjects 12 100.00 
Before treatment 































TABLE:17 VOLUME REDUCTION  GELFOAM VS  PVA 
  VOLUME %REDUCTION VOLUME %REDUCTION
1 47.07 29.8 69.82 49.5
2 164.75 39.8 71.38 23.6
3 136.66 25.3 153.76 28.0
4 51.78 9.1 94.14 30.5
5 51.4 35.8 52.3 24.8
6 120.81 25.6 171.33 27.6
7 40 11.1 122.38 29.7
8 99.23 20.2 124.26 24.4
9 170.23 44.9 167.04 40.9
10 114.22 21.3 49.81 34.5
11 99.23 12.3 126.46 38.1
12 46.6 29.2 276.14 47.8
13 62.76 33.3 52.3 26.8
14 64.72 32.6 46.6 19.9
15 144.97 47.2 127.71 33.2
AVERAGE 94.29 27.86 113.7 31.9






























 In this study 6 of them had pressure symptoms. 4 had increased frequency 
of micturation. 2 had lower abdominal heaviness. Pressure symptoms 
disappeared at 3 months for all of them. 
Table:18" Pressure Symptoms After Treatment" 
Pressure symptoms 







Total 6 nil 
 
  





















CONSOLIDATION OF RESULTS 
 
Age Mean 32.43yrs Range  26-39yrs 
Mean volume of 
fibroid 
104 cu cm Range  40.01- 276.14 cu cm 
Presenting complaints No. of 
samples 
% 
Menorrhagia 30 100.00 
Dysmenorrhoea 23 76.66 
Pressure Symptom Frequency of micturation 04 13.33 
Lower abdominal heaviness 02 06.67 
Technical difficulties 
Unilateral embolisation Vasospasm 1 3.12 
Subintimal dissection 1 3.12 
Unsuccessful 
catheterisation Vasospasm 2 6.25 
Bilateral embolisation 28 87.5 
Mean Duration of procedure 65min Range  45to 75 
min. 
Mean duration of hospital stay 
 
2.6 days Range  2-7 days 
Follow up analysis Improvement 
after 3 mths 
Improvement 
after 6 mths 
P value Inference 
Menorrhagia 83% 100% P<0.00001 Highly 
significant
Dysmenorrhoea 87% 100% P<0.00001 Highly 
significant
Volume changes 29.91% 46.66% P <0.0001 Highly 
significant
Mean volume 
reduction  Gel 
foam  vs  PVA 
Gel foam  
 
27.86% P = 1.15 Not 
significant


















































































































































































































FIG 8.7: PRE EMBOLISATION – ULTRASONOGRAPHY 
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 Fibroid uterus is one of the common benign gynaecological disorders 
encountered in the reproductive age group. Although various medical treatments 
available they are ineffective because of their side effects and temporary relief. 
Hence many young women forced to undergo hysterectomy at an early age. 
Uterine artery embolisation is minimally invasive alternative primary treatment 
of fibroids with preservation of uterus. This study was done to know the 
effectiveness, tolerability and complication of this procedure which can be used 
as primary procedure. 
 Samples were collected according to the inclusion and exclusion criteria. 
They were assessed in detail and contra-indications were ruled out. Totally 32 
samples were taken for the study. For 2 patients embolisation could not be done 
because of vasospasm. Successful embolisation was done for 30 patients. 
Hence we have analysed data for 30 patients. 
 Indication for UFE: Out of 30, 23(76.67%) of them preferred UFE to 
hysterectomy. In the remaining samples, 5 (16.67) had severe anaemia, one had 
under gone previous surgery and one was morbidly obese thus preferred UAE to 
prevent surgical and other complications. 
 Majority of the patients opted to undergo Uterine Artery Embolisation 
because of the following benefits: 
• Short duration of hospital stay. 
• Simple procedure.  
• Safe compared to hysterectomy as per previous studies 
• Satisfactory results of the previous studies.  
• Avoid surgical complications (Anaemic patients, obese patients and 
patients undergone previous surgery – anaesthetic risk, infection and 
injury to vital structure because of adhesion)  
Mean Age of the study population was 32.43 years which ranges from 
26-39. The study population below 40 years were selected because, as age 
increases associated problems like carcinoma of endometrium and ovarian 
pathologies increases which mandates surgical management. Above the age of 
40 years 3% of myomas are associated with endometrial carcinoma45. Also in 
post menopausal women and perimenopausal women the fibroid size regresses 
after menopause because of its estrogens dependent nature.  
Menorrhagia was present in all the patients which were assessed by 
Pictoral Blood Loss Assessment Chart. As per Higham et al43 who analysed 
pictoral blood loss, PBAC scoring of >100 is diagnostic of menorrhagia, that is 
blood loss of >80ml with specificity and sensitivity of >80%. All patient in 
this study had Pictoral blood loss assessment scoring of >100. Average blood 
loss scoring in this study was 202.66 and ranges from 100-315. 
        Dysmenorrhoea was present in 23(76.66%) of the subjects and was 
assessed by Visual Analogue Scale42. Before embolisation mild dysmenorrhoea 
was present in 2(7%) patients, moderate dysmenorrhoea was present in 
10(33.3%) patients and severe dysmenorrhoea in 11(37%) patients. 
  In this study Pressure Symptoms was present in only 6(20%) of the 
selected population. This may be because of the restriction of size of fibroid 
<7c.m.4 (13.33%) had increased frequency of micturation and 2(6.67%) had 
feeling of lower abdominal heaviness.  
In this study, average volume of fibroid before embolisation is 104 cu.cm. 
Largest fibroid in the study population was 10x 8x6.2 cm & volume 274.14 
cu.cm. Previously said large fibroids are associated with more complication. In 
our series we have not encountered any additional complications in larger 
fibroids. This correlates with the recent study by Albret J Smeetsetal 23 shows 
complications were not increased and clinical response is also good.  
In this study unilateral femoral puncture technique was used in all 
patients. Bilateral femoral puncture with cross-over technique which was used 
initially for UAE was faster and needs shorter screening time than unilateral 
catheterization. However, with experience, ipsi-lateral catheterization of uterine 
artery can be carried out quickly and is widely practiced today. We have used 
unilateral femoral puncture technique, not encountered any complication related 
to femoral puncture and catheterisation.This correlated with the study, Pelage 
JP, Soyer P, et al. 35, found unilateral femoral puncture was safe and with lesser 
incidence of complications such as haematoma and dissection of arteries. 
Pre procedural antibiotics and analgesics were given to all patients. None 
of the patients required any further sedatives or anaesthesia during the 
procedure.  
Successful bilateral embolisation was done for 28 (87.5%) of the patients. 
Technical difficulties was seen in 4 (12.5%) of the patients. Catheterisation of 
uterine artery could not be done because of vasospasm. Unilateral embolisation 
was done in two patient and other two patients catheterisation could not be done 
on both sides and the procedure abandoned. This is comparable with 
Brunereau et al.46 Who reported 84% successful catheterisation. Pelage et al35. 
reported successful catheterisation in 92% of cases. 
Serious complication rates in this study were 3.33% which is little higher 
compared to other studies. This can be attributed to smaller sample size. We 
have encountered one sub intimal dissection alone and no other serious 
complications like vascular perforation or allergy to contrast media noted.   
Spice et al 37 who published the largest series found an overall 8.5% short-term 
complication rate and a 1.25% serious complication rate. Infective 
complications have been noted in other studies which were not seen in this 
study. Vashisht et al.47 reported one death due to septicaemia following UAE 
leading to multiorgan failure. Walker and Pelage48 have reported three (1%) 
infective complications leading to hysterectomy. Hence, pre-existing infection 
must be excluded and proper antibiotic cover must be given before UAE. 
Expulsion of fibroids vaginally after UAE has been reported in 2.5% of patients 
by Goodwin et al.24 and Walker and Pelage48. In this study, no such incidence 
was recorded.  
Duration of the procedure varied from 45 minutes to 75 minutes. The 
average duration of the procedure was 65 minutes. This is comparable with 
results of previous researches. The mean total procedure time as reported by 
other investigators has been 78.4 min for bilateral approach18 and 44.2949 and 
6144 min for unilateral approach. Fluoroscopic exposure time was 45 min, 
which is more compared with reported times of 25.318, 13.6949 and 18.944 min. 
In this study intermittent fluoroscopy was used to reduce the exposure. 
       Post Procedural Events: Majority of the patients (90%) complained of 
pain in the lower abdominal and low back ache. Pain subsided with NSAIDs. 
Rarely narcotic analgesics needed. 20% had vomiting and 10% had fever. All 
these complications were self limiting. Patients observed for 48 hours 72 hours 
and then discharged. None of the patients developed hematoma or any other 
serious complication in immediate post procedure period. One patient had post 
embolisation syndrome (PES) and was re-admitted after a week. 
 Patients were advised to take bed rest for 6 hrs, then minimal activity upto 
24hrs, after that were ambulated well and observed in hospital. Patients without 
complications were discharged on the 2nd or 3rd day.  
Mean Duration of Hospitalisation was 2.6 days in this study. Most of the 
patients were discharged on 2nd or 3rd day. Only one patient who had sub-intimal 
dissection was discharged on 7th day. She was treated with heparin 5000u sc 
BD. MRI Scan and Doppler flow was assessed and found to be normal. Another 
patient was readmitted with the complaints of fever and myalgia. She was 
treated with antibiotics & antipyretics and was investigated for infections which 
were negative. Patient recovered after 2 days and was discharged. Pain and 
vomiting was seen in most of the patients. Pain was confined to lower abdomen 
and back region and was reduced with NSAIDS. Duration of hospital stay is 
comparable with Brunereau L, et al.46 who reported 2.3 days. In some hospitals 
the patients discharged after an over night stay. This can also suggested in 
future, as there was no complication seen after 24 hrs.  
Follow up: Patients are called at the end of 3 months and 6 months. 
Menorrhagia was assessed by Pictoral Blood Loss Assessment Chart and 
dysmenorrhea by Visual analogue Scale.USG was done to know the size of 
fibroid. 
 
 In this study on the 3rd month follow up, there was significant 
Improvement in Menorrhagia (83% of patients) (p<0.00001 highly 
significant). No patients had worsening of menorrhagia. At 6 months all (100%) 
patients had PBLA scoring below 100 that is blood loss <80 ml. It was 
comparable to the study reported by Ravina et al12 (81%) and Goodwin et al.28 
(81%). Improvement in blood loss ranges from 10 to 95 % at 3 months. At the 
6th month the improvement in menorrhagia ranges from 45 to 76%.One (3.33%) 
patient had Transient Amenorrhoea. She resumed her menstruation 4 months 
after the procedure. No cases of permanent amenorrhoea seen in this study. 
Similarly there was significant Improvement in Dysmenorrhea seen in 
87% of patients. Only 2 of the patient’s dysmenorrhea remained the same at 3 
months. At the end of 6th month none of the patients had severe dysmenorrhea. 
This results correlated with the findings of Mahmood et al.17 from Stansford 
University who showed 74% had improvement in dysmenorrhea.  
Average Volume Reduction at the 3rd month was 29.91 % (p<0.0001 
highly significant) and 6th month was 44.66%. Range of volume reduction 
varied from 9 to 50% at 3 months and 27-65% at 6 months. It comparable with 
that seen in the study by Spies et al.18, who has reported 50% at 6th month and 
78% at 1st year.  
 
Gelfoam Vs Poly Vinyl Alcohol as embolic agent: Among 30 patients in 
the study 15 of them were embolised with gel foam and remaining 15 was 
embolised with ploy vinyl alcohol particles of 350-500 µm size. On analysing 
the volume reduction, both was equally effective. This result is comparable with             
Katz et al36 who studied the effectiveness of gelatin sponge pledgets versus 















































From this study we have found that Uterine Artery Embolisation for the 
patients having symptomatic uterine fibroid is an effective and safe alternate 
treatment with significant reduction in patient’s symptoms and good patient’s 
satisfaction. It has less failure rates in short term follow up. Although long term 
follow needed to confirm it. Single femoral puncture technique can be used to 
embolise both uterine arteries successfully in most of the patients. Both the 
embolizing agents (Gel foam & PVA) are equally effective in relieving the 
symptoms. This procedure has good patient’s tolerance, short recovery time, 
quick and sustained symptomatic improvement. As the previous studies do not 
support future fertility it should be used with caution in patients who want 
future conception. Careful selection of cases and proper counselling before 
embolisation can bring maximum success to the procedure. This procedure may 
reduce the need for invasive surgery in many patients. From this study we 
conclude that UFE is a minimally invasive, safe and effective treatment for 
properly selected patients with uterine fibroids. 
LIMITATIONS OF THE STUDY: 
• Smaller sample size. 
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  Name: 
  Indication for UFE: opted / anaemia / previous surgeries / obesity / 
others 
  Age (yrs):     25-30       31-35       35-40        
  History:  
• Menorrhagia - Assessed by Pictoral Blood Loss Assessment Chart 
• Dysmenorrhoea – Assessed by Visual Analogue Scale 
• Pressure Symptoms:   Yes/no 
• Increased frequency and urgency: Yes/no 
• Lower abdominal heaviness: Yes/no 
• Constipation: Yes/no 
• Marital status: married/unmarried 
• Obstetric history: No of children    Nil /  1 / 2 /  >2 
• History of Allergy: Yes/no 
• History of previous surgeries: Yes / No 
Clinical Examination: 
• General Examination: 
 Height :  Weight:  BMI: 
 Anaemia: 





• Gynaecological Examination: 




• Blood sugar :          
• Urea:              S creatinine:  
• TC :               DC:                 ESR: 
• HIV: 
• HbsAg: 
• BT:     CT: 




• Mean Uterine sizes: 
• No. of fibroids: 
• Size of fibroids: 
• Largest axis of largest fibroid: 
• Volume of fibroid: 
• Calcification / degeneration: 
Doppler: 
• hypovascular / hypervascular 
Uterine Artery Embolisation: 
Done on: 
Duration of procedure: 
Catheterisation: unilateral/bilateral 
Embolisation: No / unilateral / bilateral 
Embolic particle used: Gel foam/PVA 
Complication During procedure:  
• Vasospasm :Yes/No 
• Vascular-perforation :Yes/No 
• Subintimal-dissection :Yes/No 
• Allergy :Yes/No 
• Mis-embolisation :Yes/No 
• Miscellaneous. 
Immediate post procedure complications  
• Pain :Yes/No 
• Vomiting :Yes/No 
• Post  embolic syndrome :Yes/No 
• Deep  vein thrombosis :Yes/No 
Late complication 
• Vaginal discharge :Yes/No 
• Fever :Yes/No 
• Trans cervical expulsion :Yes/No 
• Amenorrhoea :Yes/No 
Patient discharged on: 
Follow up at 3months: 
• Menstrual blood loss: 
• Dysmenorrhea: 
• Pressure symptom: 
• Fibroid size by USG: 
Follow up at 6months: 
• Menstrual blood loss: 
• Dysmenorrhea: 
• Pressure symptom: 



















F-Frequency of micturation 
H-Lower abdominal heaviness 
PBLA Scoring - Pictorial Blood Loss Assessment Scoring 






PES-Post embolisation syndrome 
GF-Gel Foam 
PVA-Poly Vinyl Alcohol 





UAE - Uterine Fibroid Embolization 
UFE - Uterine Fibroid Embolization 
PBLA Scoring - Pictorial Blood Loss Assessment Scoring 
VAS - Visual Analogue Scale 
USG - Ultrasound 
PES - PostEmbolisation Syndrome 
AVMs - Arterio Venous Malformations 
HRQOL - Health Related Quality Of Lifea 
 
 
 
 
 
 
 
 
 
 
 
 
 
